Mario Gabelli needs no introduction, having risen to become one of the most successful money managers on Wall Street, backed ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) ...

Biocon Biologics secures market access agreements for Yesintek, a biosimilar to Stelara, for treating autoimmune diseases in ...

TD Waterhouse Canada Inc. nearly exited its investment in Regeneron Pharmaceuticals, slashing its holdings by 98.8% in Q4, ...

Mumbai: Sanofi Consumer Healthcare India Ltd. has announced the company's Q1 results with Profit After Tax (PAT) at Rs 500 ...

MML Investors Services ramped up its Regeneron stake by 41.7%, acquiring 2,218 additional shares during Q4. This brings their ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

We recently published a list of Did Jim Cramer Nail All These 9 Stock Predictions?w. In this article, we are going to take a ...

Regeneron Pharmaceuticals has received a total of 10 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $797.9, the consensus suggests a potential 32.4% ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

US Stock Market Live | Dow Jones | Nasdaq Today | Global markets surged after Trump ruled out firing Fed Chair Powell and ...

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to broaden its capacity. Valued at more than $3bn, the partnership is set to ...